Yoshiko Nakamura

6PUBLICATIONS
58CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCardiovascular medicine and haematology not elsewhere classifiedHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|Mar 17, 2026
Fibrosis-4 Index as a Robust Long-Term Predictor of Cancers in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Ayumi Kanamoto, Teruki Miyake, Shinya Furukawa

|Aug 06, 2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada

|Jul 07, 2025
Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab.

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada

|Nov 14, 2023
Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era.

Yoshiko Nakamura, Masashi Hirooka, Atsushi Hiraoka

Pageof 1

Frequent Collaborators

6 joint publications

Masashi Hirooka

6 joint publications

Yoichi Hiasa

5 joint publications

Atsushi Hiraoka

5 joint publications

Hideko Ohama